Key facts
- This page summarizes Lincoln Alternative Strategies LLC's Form 3 filing for Calidi Biotherapeutics, Inc. (CLDI).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Aug 2025, 09:14.
Lincoln Alternative Strategies LLC - 20 Aug 2025 Form 3 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- CLDI
- Reported as of
- 20 Aug 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 27 Aug 2025, 09:14:05 UTC
- Prior SEC filing
- 27 Aug 2025
- Next SEC filing
- 29 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Temes
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lincoln Alternative Strategies LLC filed Form 3 for Calidi Biotherapeutics, Inc. (CLDI) on 27 Aug 2025.
Change
- Previous filing in this sequence was filed on 27 Aug 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002043812
Primary reporting owner
Lincoln Alternative Strategies LLC
- Relationship
- 10%+ Owner
- Address
- 404 WASHINGTON AVE., SUITE 650, MIAMI BEACH
- Signature
- /s/ Stephen Temes
- Signature date
- 27 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLDI
holding
Common Stock, par value $0.0001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 730,000
- Date
- 20 Aug 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.